Literature DB >> 28925871

Biomarkers Associated with Atrial Fibrosis and Remodeling.

Polychronis Dilaveris1, Christos-Konstantinos Antoniou1, Panagiota Manolakou1, Eleftherios Tsiamis1, Konstantinos Gatzoulis1, Dimitris Tousoulis1.   

Abstract

Atrial fibrillation is the most common rhythm disturbance encountered in clinical practice. Although often considered as solely arrhythmic in nature, current evidence has established that atrial myopathy constitutes both the substrate and the outcome of atrial fibrillation, thus initiating a vicious, self-perpetuating cycle. This myopathy is triggered by stress-induced (including pressure/volume overload, inflammation, oxidative stress) responses of atrial tissue, which in the long term become maladaptive, and combine elements of both structural, especially fibrosis, and electrical remodeling, with contemporary approaches yielding potentially useful biomarkers of these processes. Biomarker value becomes greater given the fact that they can both predict atrial fibrillation occurrence and treatment outcome. This mini-review will focus on the biomarkers of atrial remodeling (both electrical and structural) and fibrosis that have been validated in human studies, including biochemical, histological and imaging approaches. Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.

Entities:  

Keywords:  Atrial fibrillation; advanced glycosylation end-products; biomarker; collagen peptides; electrical remodeling; fibrosis; miRNAs; structural remodeling.

Mesh:

Substances:

Year:  2019        PMID: 28925871     DOI: 10.2174/0929867324666170918122502

Source DB:  PubMed          Journal:  Curr Med Chem        ISSN: 0929-8673            Impact factor:   4.530


  6 in total

1.  Blood Plasma Resistin and Atrial Fibrillation in Patients With Cardiovascular Disease.

Authors:  George Samanidis; Anastasios Gkogkos; Stefanos Bousounis; Leonidas Alexopoulos; Despina N Perrea; Konstantinos Perreas
Journal:  Cardiol Res       Date:  2020-08-01

Review 2.  Atrial Fibrillation, thromboembolic risk, and the potential role of the natriuretic peptides, a focus on BNP and NT-proBNP - A narrative review.

Authors:  Brian Kerr; Lisa Brandon
Journal:  Int J Cardiol Heart Vasc       Date:  2022-10-10

3.  NT-proANP levels in peripheral and cardiac circulation.

Authors:  Petra Büttner; Timm Seewöster; Danilo Obradovic; Gerhard Hindricks; Holger Thiele; Jelena Kornej
Journal:  J Interv Card Electrophysiol       Date:  2021-06-25       Impact factor: 1.900

4.  PU.1 inhibition attenuates atrial fibrosis and atrial fibrillation vulnerability induced by angiotensin-II by reducing TGF-β1/Smads pathway activation.

Authors:  Juan Hu; Jing-Jing Zhang; Li Li; Shan-Ling Wang; Hai-Tao Yang; Xian-Wei Fan; Lei-Ming Zhang; Guang-Ling Hu; Hai-Xia Fu; Wei-Feng Song; Li-Jie Yan; Jing-Jing Liu; Jin-Tao Wu; Bin Kong
Journal:  J Cell Mol Med       Date:  2021-06-15       Impact factor: 5.310

5.  Elevated β1-Adrenergic Receptor Autoantibody Levels Increase Atrial Fibrillation Susceptibility by Promoting Atrial Fibrosis.

Authors:  Luxiang Shang; Ling Zhang; Mengjiao Shao; Min Feng; Jia Shi; Zhenyu Dong; Qilong Guo; Jiasuoer Xiaokereti; Ran Xiang; Huaxin Sun; Xianhui Zhou; Baopeng Tang
Journal:  Front Physiol       Date:  2020-02-12       Impact factor: 4.566

Review 6.  Latest Insights into Mechanisms behind Atrial Cardiomyopathy: It Is Not always about Ventricular Function.

Authors:  Bianca-Ana Dmour; Radu-Stefan Miftode; Dan Iliescu Halitchi; Dana Teodora Anton-Paduraru; Codruta-Olimpiada Iliescu Halitchi; Ionela-Larisa Miftode; Ovidiu Mitu; Alexandru-Dan Costache; Celina-Silvia Stafie; Irina Iuliana Costache
Journal:  Diagnostics (Basel)       Date:  2021-03-05
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.